-
There was no significant association of KLK13 and KLK14 mRNA expression with the clinical factors ascitic fluid volume or residual tumor mass. High KLK14 mRNA levels were significantly associated with prolonged PFS (HR = 0.44, P = 0.017) and showed a trend towards significance for OS (HR = 0.55, P = 0.070).
-
In this work, KLK14 binding to either hepatocyte growth factor activator inhibitor type-1 (HAI-1) or type-2 (HAI-2) was essayed using homology modeling, molecular dynamic simulations and free-energy calculations through MM/PBSA and MM/GBSA. KLK14 was successfully modeled.
-
increased KLK14 activity could contribute at multiple levels to HGF/Met-mediated processes in prostate and other cancers
-
KLK7 and KLK14 gene expression can be regarded as markers of poor prognosis for colorectal cancer patients with discriminating power between CC and adenoma patients.
-
genetic variants in the KLK14 locus are associated with risk and/or aggressiveness of prostate cancer
-
KLK14, acting via PAR-2, represents an autocrine/paracrine regulator of colon tumorigenesis
-
KLK8 and KLK14 can signal differentially via the PARs to affect tissue function
-
KLK14 gene expression could be evaluated as a putative independent diagnostic biomarker in breast tumour biopsies.
-
The differences in the levels of KLK14 suggest that KLKs may aid in the differential diagnosis of salivary gland tumors. The coexpression of KLKs suggests their possible involvement in an enzymatic pathway activated in salivary gland.
-
KLK14 overexpression was found to be a significant predictor of decreased disease-free survival and overall survival in breast cancer patients
-
KLK14 expression upregulated in advanced and more aggressive prostate tumors; may play role in tumor spread and may be new marker for prostate cancer diagnosis and prognosis
-
may be part of a protease cascade in the stratum corneum, and that the observed pH effects may have physiological relevance.
-
hK14 has dual activity, trypsin- and chymotrypsin-like, with a preference for cleavage after arginine residues
-
KLK14 is clearly overexpressed in breast cancer in comparison to normal breast tissues and is positively associated with conventional parameters of tumour aggressiveness
-
The majority of KLK14 in the plantar stratum corneum is present in its catalytically active form. KLK14 could be immunohistochemically detected in sweat ducts, preferentially in the intraepidermal parts (the acrosyringium), and in sweat glands.
-
KLK14 may be implicated in several facets of tumor progression, including growth, invasion, and angiogenesis, as well as in arthritic disease via deterioration of cartilage
-
KLK14 may participate in epidermal desquamation through cleavage of desmoglein 1 and regulation by lympho-epithelial Kazal-type-related inhibitor (LEKTI).
-
KLK5 and KLK14, but neither KLK7 nor KLK8, induced PAR2 signalling.
-
KLK14 is a new activator component of the KLK proteolytic cascade with a possible role in seminal plasma and skin
-
semenogelins I and II were directly cleaved by KLK14. Semenogelins were also able to reverse KLK14 inhibition by Zn2+, providing a novel regulatory mechanism for KLK14 activity.
